irinotecan has been researched along with Chronic Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beige, A; Borsotti, F; Farah, W; Ghiringhelli, F; Ilie, SM; Lecuelle, J; Mazilu, I; Truc, G; Truntzer, C; Vincent, J | 1 |
| d'Esposito, F; Edwards, RJ; Murray, M; Nebot, N | 1 |
| Chu, F; Chua, TC; Liauw, W; Morris, DL | 1 |
| Gil Delgado, M; Khayat, D; Spano, JP | 1 |
1 review(s) available for irinotecan and Chronic Disease
| Article | Year |
|---|---|
Cetuximab plus irinotecan in refractory colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chronic Disease; Colorectal Neoplasms; Humans; Irinotecan | 2007 |
3 other study(ies) available for irinotecan and Chronic Disease
| Article | Year |
|---|---|
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.
Topics: Bevacizumab; Chronic Disease; Cytotoxins; Glioblastoma; Humans; Irinotecan; Recurrence; Retrospective Studies; Temozolomide | 2022 |
Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
Topics: Antineoplastic Agents; Biotransformation; Camptothecin; Carboxylesterase; Chronic Disease; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Down-Regulation; Humans; Irinotecan; Liver Diseases; Microsomes, Liver | 2010 |
Viewing metastatic colorectal cancer as a curable chronic disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Bevacizumab; Camptothecin; Cetuximab; Chronic Disease; Colorectal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Metastasectomy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Recurrence; Reoperation; Survival Rate | 2012 |